Genentech Submits New Drug Application to FDA for Venclexta Plus Gazyva for Untreated CLL with Co-Existing Medical Conditions Interview with:

Nancy Valente, M.D.VP of Global Hematology DevelopmentGenentech

Dr. Valente

Nancy Valente, M.D.
VP of Global Hematology Development

Dr. Valenta discusses the announcement of the submission by Genentech of a supplemental New Drug Application to the FDA for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukemia  with co-existing medical conditions. What is the background for this study?
What are the main findings of the Phase III CLL14 study? 

Response: We completed the submission of a supplemental New Drug Application (sNDA) to the FDA for Venclexta® (venetoclax) in combination with Gazyva® (obinutuzumab) in people with previously untreated chronic lymphocytic leukemia (CLL) and co-existing medical conditions. CLL is the most common form of adult leukemia and more than 20,000 new cases will be diagnosed in the U.S. this year.

The sNDA is based on data from the Phase III CLL14 study, which evaluated fixed-duration Venclexta in combination with Gazyva in people with previously untreated CLL. Results showed this chemotherapy-free combination can help people with previously untreated CLL live significantly longer without their disease worsening (progression-free survival; PFS) compared to standard-of-care Gazyva plus chlorambucil.

The FDA is reviewing our application under the Real-Time Oncology Review (RTOR) pilot program, which is exploring a more efficient review process to ensure safe and effective treatments are available to patients as early as possible.  Continue reading

Phase I Study T-cell Bispecific Antibody For Aggressive Non-Hodgkin’s Lymphoma Interview with:

Dr-Nancy Valente

Nancy Valente, M.D.,
Vice President, Global Hematology Development
Genentech  What is the background for this study?

Response: Despite advances in treatments for people with relapsed or refractory (R/R) NHL, a substantial number of patients do not sustain a response to standard-of-care treatment, meaning new options are needed. For example, as many as 40 percent of people with diffuse largeB-cell lymphoma (DLBCL), an aggressive form of NHL, eventually relapse after initial treatment. Different mechanisms of action and different therapy combinations may help improve clinical outcomes in patients with R/R NHL.

At ASH, we presented initial safety and efficacy results from a Phase I study of our T-cell bispecific antibody, CD20-TCB, as a monotherapy in patients with R/RNHL. What are the main findings?

Response: The preliminary results suggest thatCD20-TCB monotherapy have promising clinical activity and may induce durable complete responses in patients with late-line R/R aggressive NHL. In patients with aggressive NHL who received the highest tested dose roughly half (53 percent) of patients responded (objective response rate)to treatment and nearly a third (27 percent) saw the disappearance of all signs of cancer (complete response). Importantly, all complete responses have been sustained so far, with a median follow up of roughly three months (94 days). These responses are particularly encouraging since aggressive forms of NHL become harder to treat with each relapse.

Patient sin the study had previously received a median of three lines of therapy, with a range of 1-13 lines. Most were refractory to their most recent therapy (72percent) and refractory to prior treatment with an anti-CD20 antibody (74percent). What should readers take away from your report?

Response: CD20-TCB is one of two bispecific antibodies we are developing that are designed to target CD20 and CD3. At ASH, we also presented data for mosunetuzumab. The results from the first clinical trials of these bispecific antibodies showed promising clinical activity and durable complete responses inpatients with R/R NHL. We are excited by the potential to harness the dual-targeting ability of CD20-CD3 bispecific antibodies to treat blood cancers and encouraged by these early results. We continue to study CD20-TCB and mosunetuzumab as potential new treatment options for patients with R/R NHL, an area of high unmet need. What recommendations do you have for future research as a result of this work?

Response: Bispecific antibodies can recognize and bind to two different targets simultaneously, and in doing so, combine the binding specificity of two antibodies in one molecule. In the treatment of cancer, bispecific antibodies are designed to physically link a cancer cell to an immune cell which leads to the destruction of the cancer cell by the patient’s immune system, representing a novel approach for the treatment of cancers.

CD20-Tcb (RG6026), a Novel “2:1” FormatT-Cell-Engaging Bispecific Antibody, Induces Complete Remissions inRelapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma: Preliminary Results from aPhase I First in Human Trial

ASH 2018, December 1, 2018: 4:45 PM

MartinHutchings, MD, PhD1*,Gloria Iacoboni, MD2*, Franck Morschhauser,MD3*, Fritz Offner, MD4, AnnaSureda, MD5*, Gilles Andre Salles, MD, PhD6,Carmelo Carlo-Stella, MD7,Joaquin Martinez Lopez, MD8*,Denise Thomas, BS9*, Peter N Morcos, PhD10*, BetsyQuackenbush, MD9*, Cristiano Ferlini, MD11*,Marina Bacac, PhD12*, Ann-Marie E. Broeske,PhD13*, Natalie Dimier, PhD14*, TomMoore, MD11*, Martin Weisser, MD15* andMichael Dickinson, MBBS, FRACP, FRCPA16


The information on is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

FDA Approves Single Dose XOFLUZA™ For Uncomplicated Flu Interview with:

Mark D. Eisner, MD, MPH Vice President, Product Development Immunology Infectious Disease and Ophthalmology Genentech 

Dr. Mark Eisner

Mark D. Eisner, MD, MPH
Vice PresidentProduct Development Immunology, Infectious Disease and Ophthalmology Genentech

Dr. Eisner discusses the announcement that the FDA has approved XOFLUZA™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza. What is the background for this announcement?

Response: Each year, an estimated 3-11 percent of the U.S. population gets the flu, and it can be very serious, resulting in hospitalization or even death. Since 2010, the Centers for Disease Control and Prevention (CDC) estimates that the flu has resulted annually in 9.2 to 35.6 million illnesses, 140,000 to 900,000 hospitalizations and 12,000 to 80,000 deaths. The severity of last year’s flu season underscores the need for new medical options beyond currently available antivirals.

XOFLUZA was granted Priority Review in June 2018 based on results from the Phase III CAPSTONE-1 study of a single dose of XOFLUZA compared with placebo or oseltamivir 75 mg, twice daily for five days, in otherwise healthy people with the flu, as well as results from a placebo-controlled Phase II study in otherwise healthy people with the flu.

Continue reading

Flu: Novel Oral Single Dose Antiviral Baloxavir Marboxil Reduced Symptoms in High Risk Patients Interview with:

Mark Eisner MD MPH Vice President and Global Head of Respiratory Actemra, ID, and Metabolism Clinical Development at Genentech Professor of Clinical Medicine University of California, San Francisco

Dr. Mark Eisner

Mark Eisner MD MPH

Mark D. Eisner, MD, MPH
Vice President, Product Development Immunology, Infectious Disease, and Ophthalmology
Genentech What is the background for this study?
Would you briefly explain how 
baloxavir marboxil differs from other flu treatments? 

Response: CAPSTONE-2 is a Phase III multicenter, randomized, double-blind study that evaluated a single dose of baloxavir marboxil compared with placebo and oseltamivir in people 12 years and older who are at a high risk of complications from the flu. The high risk inclusion criteria in CAPSTONE-2 were aligned with the Centers for Disease Control and Prevention (CDC), which defines people at high risk for serious flu complications to include adults 65 years of age or older, or those who have conditions such as asthma, chronic lung disease, diabetes or heart disease. For these people, flu can lead to hospitalization or even death. Participants enrolled in the study were randomly assigned to receive a single dose of 40 mg or 80 mg of baloxavir marboxil (according to body weight), placebo or 75 mg of oseltamivir twice a day for five days.

The FDA recently accepted a New Drug Application (NDA) and granted Priority Review to baloxavir marboxil as a single-dose, oral treatment for acute, uncomplicated influenza in people 12 years and older. The NDA was based on results from the Phase III CAPSTONE-1 study of a single dose of baloxavir marboxil compared with placebo or oseltamivir 75 mg, twice daily for five days, in otherwise healthy people with the flu. Results from a placebo-controlled Phase II study in otherwise healthy people with the flu were included as supporting data in the NDA. The FDA is expected to make a decision on approval by December 24, 2018.

Baloxavir marboxil is a first-in-class, single-dose investigational oral medicine with a novel proposed mechanism of action designed to target the influenza A and B viruses, including oseltamivir-resistant strains and avian strains (H7N9, H5N1). Unlike other currently available antiviral treatments, baloxavir marboxil is the first in a new class of antivirals designed to inhibit the cap-dependent endonuclease protein within the flu virus, which is essential for viral replication. By inhibiting this protein, baloxavir marboxil prevents viral replication earlier in the flu virus life cycle. Continue reading